MTHFR 677C/T基因多态性与培美曲塞对晚期肺腺癌患者疗效的关系

目的 探索亚甲基四氢叶酸还原酶(methylenetetrahydrofolate reductase,MTHFR)677C/T基因多态性在预测培美曲塞治疗晚期肺腺癌疗效中的作用.方法 39例初治晚期肺腺癌患者入组并行培美曲塞/顺铂方案化疗,37例患者按要求完成治疗并进行随访.通过Taqman MGB探针实时荧光定量PCR方法检测患者MTHFR677 C/T位点的基因多态性,分析基因多态性与化疗客观缓解率(response rate,RR)和无进展生存时间(progressionfree survival,PFS)的关系.结果 MTHFR 677C/T基因频率:CC 40.5％ (15/37),CT 43.2％(16/37),TT16.2％ (6/37),MTHFR CC、CT和TT基因型客观缓解率之间差异无统计学意义(26.7％ vs 31.3％vs50.0％,P=0.582).CC基因型与CT或TT基因型之间PFS差异无统计学意义(4.7月vs 6.9月,P=0.499).结论 MTHFR 677C/T多态性可能与晚期肺腺癌培美曲塞化疗疗效无相关性.

Association of MTHFR 677C/T gene polymorphism with therapeutic effect of pemetrexed in advanced lung adenocarcinoma

Objective To investigate the association of methylenetetrahydrofolate reductase（MTHFR） gene polymorphism with the therapeutic effect of pemetrexed in advanced lung adenocarcinoma.Methods Thirty-nine patients with advanced lung adenocarcinoma were enrolled in this study and treated with pemetrexed plus cisplatin.Thirty-seven finished the treatment and were followed up.MTHFR 677C/T gene polymorphism was determined in blood samples from the patients by quantitative real-time PCR using Taqman MGB probes.The relationship between gene polymorphism,response rate and progression-free survival was analyzed.Results The percentages of CC,CT and TT genotypes in MTHFR（rs1801133） were 40.5%,43.2% and 16.2%.The response rates of patients with genotype CC,CT and TT were not statistically different（26.7% vs 31.3% vs 50.0%,P=0.582）.No significant difference in progression-free survival was observed between patients with genotype CC and CT or TT（4.7 m vs 6.9 m,P=0.499）.Conclusion There is no association between MTHFR 677C/T gene polymorphism and response in patients with advanced lung adenocarcinoma receiving pemetrexed/cisplatin chemotherapy.